Ubs Group Ag Atai Life Sciences N.V. Transaction History
Ubs Group Ag
- $555 Billion
- Q2 2025
A detailed history of Ubs Group Ag transactions in Atai Life Sciences N.V. stock. As of the latest transaction made, Ubs Group Ag holds 7,699,759 shares of ATAI stock, worth $31.8 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
7,699,759
Previous 5,535,482
39.1%
Holding current value
$31.8 Million
Previous $7.53 Million
123.99%
% of portfolio
0.0%
Previous 0.0%
Shares
16 transactions
Others Institutions Holding ATAI
# of Institutions
110Shares Held
31.3MCall Options Held
494KPut Options Held
315K-
Adage Capital Partners Gp, L.L.C. Boston, MA5.43MShares$22.4 Million0.02% of portfolio
-
Morgan Stanley New York, NY3.49MShares$14.4 Million0.0% of portfolio
-
Pale Fire Capital Se Prague, 2N2.64MShares$10.9 Million0.59% of portfolio
-
Black Rock Inc. New York, NY1.31MShares$5.4 Million0.0% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny1.19MShares$4.91 Million0.0% of portfolio
About ATAI Life Sciences N.V.
- Ticker ATAI
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 165,875,008
- Market Cap $685M
- Description
- Atai Life Sciences N.V., through its subsidiary, ATAI Life Sciences AG, operates as a clinical-stage biopharmaceutical company. It engages in developing various therapeutic candidates that focuses on various mental health disorders. The company's therapeutic candidates include PCN-101, a subcutaneous formulation of R-ketamine for the treatment o...